产品
编 号：F014630
分子式：C23H28N4O4S
分子量：456.56
分子式：C23H28N4O4S
分子量：456.56
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1032823-75-8
产品详情
生物活性：
GSK-1292263 is an orally available GPR119 agonist with pEC50s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM).
体内研究：
GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats.Animal Model:Male neonatal Streptozotocin (STZ)-induced SD rats (7 weeks of age)
Dosage:30 mg/kg
Administration:Orally given; once a day for 2 weeks
Result:The AUC of plasma glucose (AUCPG) in the single treatment of the GSK1292263 group was numerically lower than that of the vehicle group, but the effect was modest.
GSK-1292263 is an orally available GPR119 agonist with pEC50s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM).
体内研究：
GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats.Animal Model:Male neonatal Streptozotocin (STZ)-induced SD rats (7 weeks of age)
Dosage:30 mg/kg
Administration:Orally given; once a day for 2 weeks
Result:The AUC of plasma glucose (AUCPG) in the single treatment of the GSK1292263 group was numerically lower than that of the vehicle group, but the effect was modest.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备